Taubman Scholars Clinical Trials

Current clinical trials ~ November 2012

Nicholas M. Boulis, M.D., Associate Professor of Neurosurgery, Emory School of Medicine

  • Human spinal cord derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis (ALS) – with Eva Feldman, M.D., Ph.D.

Frank C. Brosius III, M.D., Professor of Internal Medicine and Molecular and Integrative Physiology; Chief, Division of Nephrology

  • Phase 2 study to evaluate the safety and renal efficacy of LY3009104 in patients with diabetic kidney disease

Ronald J. Buckanovich, M.D., Ph.D., Marvin and Betty Danto Foundation Emerging Scholar; Assistant Professor of Internal Medicine and of Obstetrics and Gynecology

  • Evaluate metformin, targeting cancer stem cells for the prevention of   relapse in patients with stage IIC/III/IV ovarian, fallopian tube, and primary peritoneal cancer

Charles F. Burant, M.D., Ph.D., Robert C. and Veronica Atkins Professor of Metabolism, Professor of Internal Medicine, and Molecular and Integrative Physiology; Director, U-M Metabolomics and Obesity Center

  • Identification of phenotypic factors predicting success for weight loss and long-term weight maintenance
  • Effects of intensive lifestyle intervention in obese subfertile women on reproductive outcomes
  • Cognitive control and obesity
  • Impact of metabolic syndrome on the incidence of neuropathy in obese subjects

James J. Dowling, M.D., Ph.D., Frances and Kenneth Eisenberg Emerging Scholar; Assistant Professor of Pediatrics and Communicable Diseases and of Neurology; Director, Muscular Dystrophy Clinic

  • Examine mestinon in centronuclear myopathy patients
  • Identify new genes and new mutant alleles responsible for previously unrecognized inherited neurologic disorders
  • Document natural history of centronuclear myopathy and define possible targets for treatment

Theodore S. Lawrence, M.D., Ph.D., Isadore Lampe Collegiate Professor of Radiation Oncology; Chair, Department of Radiation Oncology

  • Assessment of liver function in patients undergoing hepatic irradiation
  • Pilot study of radiation toxicity using MRI-based perfusion
  • Pilot study of changes in hepatic function during radiation therapy using hepatobiliary SPECT
  • Phase II study of individualized steroactic body radiation therapy (SBRT)

Valerie P. Castle, M.D., Ravitz Foundation Professor and Chair, Department of Pediatrics and Communicable Diseases; Professor of Pediatric Hematology/Oncology

  • Study of Irinotecan and Bortezomib in children with recurrent/refractory neuroblastoma

Eva L. Feldman. M.D., Ph.D., Russell N. DeJong Professor of Neurology; Director, A. Alfred Taubman Medical Research Institute; Director, Program for Neurology Research & Discovery; Director of Research, ALS Clinic

  • Human spinal cord derived neural stem cell transplantation for the treatment of amyotrophic lateral sclerosis (ALS) – with Dr. Boulis
  • Targeting Inflammation Using Salsalate in Type 1 Diabetic Neuropathy
  • Surveillance, Natural History, Quality of Care and Outcomes of Diabetes Mellitus with Onset in Childhood and Adolescence
  • Impact of the Metabolic Syndrome on Incidence of Neuropathy in Obese Subjects
  • Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy
  • Neuropathy in Epidemiology of Diabetes Interventions & Complications Cohort
  • Phase 2b Trial to Assess the Safety and Efficacy of Long lasting synthetic C-Peptide in Type 1 Diabetes Subjects with Mild to Moderate Diabetic Peripheral Neuropathy
  • Phase 2b study to assess the effect of CK-2017357 after 12 weeks of oral dosing in patients with ALS

Max S. Wicha, M.D., Distinguished Professor of Oncology, Professor of Internal Medicine; Director, U-M Comprehensive Cancer Center

  • Targeting intrinsically-resistant breast cancer stem cells with Gamma-Secretase inhibitors
  • Phase I dose-escalation study of the hedgehog smoothened antagonist GDC-0449 plus pan-notch inhibitor RO4929097 administered in patients with advanced breast cancer
  • Dose escalation study of OMP-59R5 in subjects with solid tumors
  • Dose escalation study of OMP-54F28 in subjects with solid tumors
  • First in-human Phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer in patients with advanced solid tumors
  • Phase I study of Akt inhibitor plus Lapatinib in patients with breast cancer
  • Phase I study of Repartaxin in patients with breast cancer
  • Tositumomab (Bexxar) in patients with myeloma


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift


Follow Us / Friend Us

Discovery-driven research that matters


Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding


The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more

Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  


Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster


video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists